PT - JOURNAL ARTICLE AU - Andrew Moore AU - Mingdong Lyu AU - Randolph Hall TI - Tracking COVID-19 Cases and Deaths in the United States: Distribution of Events by Day of Pandemic AID - 10.1101/2021.08.30.21262851 DP - 2021 Jan 01 TA - medRxiv PG - 2021.08.30.21262851 4099 - http://medrxiv.org/content/early/2021/09/03/2021.08.30.21262851.short 4100 - http://medrxiv.org/content/early/2021/09/03/2021.08.30.21262851.full AB - In this paper, we analyze the progression of COVID-19 in the United States over a nearly one-year period beginning March 1, 2020, with a novel metric representing the partial-average day-of-event, where events are new cases and new deaths. The metric is calculated as a function of date and location to illustrate patterns of disease, showing growing or waning cases and deaths. The metrics enable the direct comparison of the time distribution of cases and deaths, revealing data coherence and how patterns varied over a one-year period. We also compare different methods of estimating actual infections and deaths to better understand on the timing and dynamics of the pandemic by state. We used three example states to graphically compare metrics as functions of date and also compared statistics derived from all 50 states. Over the period studied, average case day and average death day vary by two to five months among the 50 states, depending on data source, with the earliest averages in New York and surrounding states, as well as Louisiana. The average day of death has preceded the average day of case in Centers for Disease Control (CDC) data for most states and most dates since June of 2020. In contrast, “COVID-19 Projections” more closely align deaths and cases, which are similarly distributed.Competing Interest StatementThe authors have declared no competing interest.Funding StatementResearch was supported by the University of Southern California through the Zumberge Innovation Fund and the Center for Undergraduate Research in Viterbi Engineering (CURVE).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Our research does not involve any biomedical or social-behavioral in nature.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data is available on the website and could be used under permission. https://covid19datasource.usc.edu/